breakthrough device

Integrating music, movement and stroke rehabilitation, MedRhythms raises $25M to develop and commercialize digital therapeutic

by

MedRhythms rais­es 25m to get patients back in tune after a stroke (TechCrunch):

MedRhythms secured $25 mil­lion in Series B fund­ing to advance its dig­i­tal ther­a­py plat­form aimed at mea­sur­ing and improv­ing someone’s abil­i­ty to walk after they have expe­ri­enced a neu­ro­log­ic injury or dis­ease … Com­pa­ny co-founder and CEO Bri­an Har­ris was a neu­ro­log­ic music fel­low at Spauld­ing Reha­bil­i­ta­tion Hos­pi­tal in Boston, treat­ing peo­ple with stroke and brain deficits with music. He began get­ting ques­tions from patients and fam­i­lies on how they could access sim­i­lar care out­side of the hos­pi­tal. Not see­ing a suit­able alter­na­tive, he start­ed MedRhythms with entre­pre­neur Owen McCarthy in 2016. [Read more…] about Inte­grat­ing music, move­ment and stroke reha­bil­i­ta­tion, MedRhythms rais­es $25M to devel­op and com­mer­cial­ize dig­i­tal therapeutic

Neurostimulation device GammaSense by Cognito Therapeutics secures FDA Breakthrough Device Designation to explore Alzheimer’s Disease applications

by

Cred­it: The Picow­er Insti­tute @ MIT

Cog­ni­to Ther­a­peu­tics nets FDA break­through label for light, sound ther­a­py for Alzheimer’s dis­ease (Fierce Biotech):

Using spe­cif­ic fre­quen­cies of flash­ing lights and sounds to stim­u­late the brain’s elec­tri­cal activ­i­ty, Cog­ni­to Ther­a­peu­tics believes it can help treat Alzheimer’s dis­ease by ener­giz­ing neu­rons and reac­ti­vat­ing the immune system.

[Read more…] about Neu­rostim­u­la­tion device Gam­maSense by Cog­ni­to Ther­a­peu­tics secures FDA Break­through Device Des­ig­na­tion to explore Alzheimer’s Dis­ease applications

Neuromodulation device Relivion gets FDA clearance to help patients with major depression who don’t benefit from antidepressant medications

by

Neu­rolief wins FDA break­through nod for wear­able neu­ro­mod for depres­sion (Mass Device):

Neu­rolief announced today that it received FDA break­through device des­ig­na­tion for its Reliv­ion DP sys­tem for treat­ing major depression.

Reliv­ion is a wear­able, non-inva­sive, mul­ti-chan­nel brain neu­ro­mod­u­la­tion device designed as an adjunc­tive treat­ment to phar­ma­ceu­ti­cal man­age­ment of major depres­sive dis­or­der (MDD) in adults who haven’t expe­ri­enced sat­is­fac­to­ry improve­ment from anti­de­pres­sant med­ica­tions, accord­ing to a news release. [Read more…] about Neu­ro­mod­u­la­tion device Reliv­ion gets FDA clear­ance to help patients with major depres­sion who don’t ben­e­fit from anti­de­pres­sant medications